Halberd Corporation2020-09-14T13:05:54-04:00

Moving Forward

Halberd Corporation (HALB) patented extracorporeal treatment is applicable to many hard-to-cure blood-borne and neurologic diseases, including Covid-19, other viruses, PTSD, cancer, etc.

COVID-19

Halberd Corporation (HALB) patented extracorporeal treatment is applicable to many hard-to-cure blood-borne and neurologic diseases, including Covid-19, other viruses, PTSD, cancer, etc.

PTSD

Halberd Corporation (HALB) patented extracorporeal treatment is applicable to many hard-to-cure blood-borne and neurologic diseases, including Covid-19, other viruses, PTSD, cancer, etc.

Chronic Traumatic Encephalopathy

Halberd Corporation (HALB) patented extracorporeal treatment is applicable to many hard-to-cure blood-borne and neurologic diseases, including Covid-19, other viruses, PTSD, cancer, etc.

Cancer

Halberd Corporation (HALB) patented extracorporeal treatment is applicable to many hard-to-cure blood-borne and neurologic diseases, including Covid-19, other viruses, PTSD, cancer, etc.

Halberd Corporation has acquired exclusive licenses to two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and Cerebrospinal Fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other virus’. The issued patents’ extracorporeal technology is applicable to a significant number of the most debilitating and often fatal illnesses affecting mankind: PTSD, CTE (Chronic Traumatic Encephalopathy) and Cancer, among others.

We have developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials. In addition, we have initiated the development of potential patient trial application lists. Our management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment.

Halberd Corporation Fact Sheet

A brief review of some of Halberd’s significant accomplishments and recent developments.

PROPRIETARY SEQUENTIAL DIALYSIS TECHNIQUE

A methodology that physically removes the pathophysiologic basis of the disease

The Company’s proprietary Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without dangerous side effects.

  • Superior to current treatments which eliminate the presence of most illnesses but often with catastrophic or even fatal side effects.
  • Subtractive therapy (removal of harmful molecules) reduces risks associated with conventional “Additive” therapy (adding chemicals to the body).
  • Targets Covid-19 and similar viral diseases initially, with future efforts to develop treatments for Alzheimer’s Disease, PTSD/Traumatic Brain Injury, and cancer.
View all patents

Halberd News

Press releases and updates on our medical breakthroughs.

Halberd’s PTSD/Alzheimer’s R&D Reveals Link to Potential Obesity Cure

Jackson Center, PA, October 20, 2021 – Halberd Corporation’s (OTC-PINK: HALB) ongoing research into discovering treatments/cures for PTSD, Alzheimer’s Disease, and other neurodegenerative diseases has led to a potential breakthrough in the battle against obesity.  Research has indicated inflammatory cytokines present in the Cerebral Spinal Fluid (CSF) of neurodegenerative disease patients are ...

Insulin Resistance Associated To Obesity: The Link TNF-Alpha

Iria Nieto-Vazquez, Sonia Fernández-Veledo, David K. Krämer,Rocio Vila-Bedmar, Lucia Garcia-Guerra & Margarita Lorenzo Abstract Adipose tissue secretes proteins which may influence insulin sensitivity. Among them, tumour necrosis factor (TNF)-alpha has been proposed as a link between obesity and insulin resistance because TNF-alpha is overexpressed in adipose tissue from obese animals and humans, ...

View all news
Go to Top